Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis

Arthritis and Rheumatism

Volumn 64, Issue 5, 2012, Pages 1388-1398

  Poddubnyy, Denis ^a   Haibel, Hildrun ^a   Listing, Joachim ^b   Märker Hermann, Elisabeth ^c   Zeidler, Henning ^d   Braun, Jürgen ^e   Sieper, Joachim ^a   Rudwaleit, Martin ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Rheumatism Research Centre   (Germany)

^c DR HORST SCHMIDT KLINIKEN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e RHEUMAZENTRUM RUHRGEBIET   (Germany)

^f Evangelisches Krankenhaus Hagen Haspe   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA B27 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGE; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BONE GROWTH; CIGARETTE SMOKING; COHORT ANALYSIS; DISEASE COURSE; DISEASE DURATION; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; SACROILIITIS; SEX; SPINE RADIOGRAPHY; SYNDESMOPHYTE;

ADULT; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COMORBIDITY; DISEASE PROGRESSION; FEMALE; GERMANY; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; OSTEOPHYTE; PROSPECTIVE STUDIES; SMOKING; SPINE; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; TOBACCO USE DISORDER;

EID: 84860436138     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33465     Document Type: Article

References (53)

1. Van der Linden S, Valkenburg HA, Cats A,. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
2. Rudwaleit M, Khan MA, Sieper J,. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005; 52: 1000-8.
3. Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68: 770-6.
4. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777-83.
5. Braun J, Sieper J,. Ankylosing spondylitis. Lancet 2007; 369: 1379-90.
6. Creemers MC, Franssen MJ, van 't Hof MA, Gribnau FW, van de Putte LB, van Riel PL,. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005; 64: 127-9.
7. Machado P, Landewe R, Braun J, Hermann KG, Baker D, van der Heijde D,. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010; 69: 1465-70.
8. Wanders AJ, Landewe RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum 2004; 50: 2622-32.
9. MacKay K, Mack C, Brophy S, Calin A,. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 1998; 41: 2263-70.
10. Averns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT,. Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol 1996; 35: 373-6.
11. Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007; 66: 910-5.
12. Baraliakos X, Listing J, von der Recke A, Braun J,. The natural course of radiographic progression in ankylosing spondylitis: evidence for major individual variations in a large proportion of patients. J Rheumatol 2009; 36: 997-1002.
13. Atagunduz P, Aydin SZ, Bahadir C, Erer B, Direskeneli H,. Determinants of early radiographic progression in ankylosing spondylitis. J Rheumatol 2010; 37: 2356-61.
14. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009; 60: 717-27.
15. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al, for the European Spondylarthropathy Study Group. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218-27.
16. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A,. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
17. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5.
18. Wanders A, Landewe R, Spoorenberg A, de Vlam K, Mielants H, Dougados M, et al. Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order. Ann Rheum Dis 2004; 63: 1601-4.
19. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J,. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab. Ann Rheum Dis 2005; 64: 1462-6.
20. Bruynesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D,. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005; 64: 179-82.
21. Bathke A, Brunner E,. A nonparametric alternative to analysis of covariance. In:, Akritas MG, Politis DN, editors. Recent advances and trends in nonparametric statistics. Amsterdam: Elsevier Science & Technology; 2003. p. 109-20.
22. Newcombe RG,. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857-72.
23. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Rates and predictors of radiographic sacroiliitis progression over two years in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 1369-74.
24. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 years of treatment with the anti-TNF-α antibody infliximab. Rheumatology (Oxford) 2007; 46: 1450-3.
25. Van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al, and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58: 3063-70.
26. Van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58: 1324-31.
27. Van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009; 11: R127.
28. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J,. Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. Arthritis Rheum 2009; 61: 764-71.
29. Van der Heijde D, Landewe R, van der Linden S,. How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? Arthritis Rheum 2005; 52: 1979-85.
30. Wanders A, van der Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52: 1756-65.
31. Van Tubergen A, Ramiro S, van der Heijde D, Dougados M, Mielants H, Landewe R,. Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis 2011. E-pub ahead of print.
32. Maksymowych WP, Landewe R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007; 56: 1846-53.
33. Amor B, Santos RS, Nahal R, Listrat V, Dougados M,. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994; 21: 1883-7.
34. Sieper J, Appel H, Braun J, Rudwaleit M,. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes [review]. Arthritis Rheum 2008; 58: 649-56.
35. Schett G, Landewe R, van der Heijde D,. Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis 2007; 66: 709-11.
36. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009; 60: 3257-62.
37. Sieper J, Appel H, Rudwaleit M, Haibel H, Poddubnyy D, Baraliakos X, et al. Inverse correlation between serum levels of Dickkopf 1 (DKK1) and new bone formation in ankylosis spondylitis patients. Ann Rheum Dis 2010; 69 Suppl 3: iii442.
38. Schett G, Rudwaleit M,. Can we stop progression of ankylosing spondylitis? Best Pract Res Clin Rheumatol 2010; 24: 363-71.
39. Averns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT,. Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol 1996; 25: 138-42.
40. Doran MF, Brophy S, MacKay K, Taylor G, Calin A,. Predictors of longterm outcome in ankylosing spondylitis. J Rheumatol 2003; 30: 316-20.
41. Kaan U, Ferda O,. Evaluation of clinical activity and functional impairment in smokers with ankylosing spondylitis. Rheumatol Int 2005; 25: 357-60.
42. Ward MM, Weisman MH, Davis JC Jr, Reveille JD,. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 2005; 53: 710-7.
43. Ward MM, Hendrey MR, Malley JD, Learch TJ, Davis JC Jr, Reveille JD, et al. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheum 2009; 61: 859-66.
44. Klareskog L, Padyukov L, Alfredsson L,. Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol 2007; 19: 49-54.
45. Baka Z, Buzas E, Nagy G,. Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther 2009; 11: 238.
46. Bang SY, Lee KH, Cho SK, Lee HS, Lee KW, Bae SC,. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status. Arthritis Rheum 2010; 62: 369-77.
47. Carlens C, Hergens MP, Grunewald J, Ekbom A, Eklund A, Hoglund CO, et al. Smoking, use of moist snuff, and risk of chronic inflammatory diseases. Am J Respir Crit Care Med 2010; 181: 1217-22.
48. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, et al, and the other members of the EIRA study group. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003; 62: 835-41.
49. Smolen JS, Emery P, Keystone EC, Breedveld F, Betteridge N, Burmester G, et al, the Working Group on the Rituximab Consensus Statement. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 143-50.
50. Costenbader KH, Kim DJ, Peerzada J, Lockman S, Nobles-Knight D, Petri M, et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004; 50: 849-57.
51. Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML,. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol 2010; 25: 325-33.
52. Finckh A, Dehler S, Costenbader KH, Gabay C,. Cigarette smoking and radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1066-71.
53. Saevarsdottir S, Wedren S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011; 63: 26-36.